<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01979510</url>
  </required_header>
  <id_info>
    <org_study_id>0663B-164</org_study_id>
    <nct_id>NCT01979510</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)</brief_title>
  <official_title>A Phase III Randomized Clinical Trial to Evaluate the Safety and Efficacy of an Etoricoxib and Tizanidine Fixed Dose Combination in Subjects With Moderate to Severe Acute Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of MK-0663B
      (etoricoxib/tizanidine) among participants with moderate-to-severe acute low back pain.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to Day 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Treatment Due to an AE</measure>
    <time_frame>Up to Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Participant Low Back Pain Questionnaire Score</measure>
    <time_frame>Baseline and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Participant Roland Morris Disability Questionnaire</measure>
    <time_frame>Baseline and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ≥30% Improvement From Baseline in the Roland Morris Disability</measure>
    <time_frame>Baseline and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Participant Global Assessment of Response to Therapy.</measure>
    <time_frame>Baseline and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Investigator Global Assessment of Response to Therapy</measure>
    <time_frame>Baseline and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Amount of Rescue Medication Required by Participant During Study Treatment</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Using Rescue Medication During Study Treatment</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>MK-0663B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-0663B (etoricoxib 90 mg immediate release [IR]/tizanidine 6 mg modified release [MR]) capsules once daily for 8 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOLOCAM PLUS®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0663B</intervention_name>
    <description>MK-0663B once daily for 8 days.</description>
    <arm_group_label>MK-0663B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOLOCAM PLUS®</intervention_name>
    <description>DOLOCAM PLUS® once daily for 8 days.</description>
    <arm_group_label>DOLOCAM PLUS®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen 500 mg</intervention_name>
    <description>Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.</description>
    <arm_group_label>MK-0663B</arm_group_label>
    <arm_group_label>DOLOCAM PLUS®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have acute low back pain;

          -  Onset of acute low back pain must be &lt;6 weeks prior to screening;

          -  Have acute low back pain corresponding to a rating of ≥ 4 on a 0-10 point Low Back
             Pain Questionnaire and ≥ 7 on the Roland Morris Questionnaire;

          -  For women of childbearing potential, have a negative serum pregnancy test at Visit 1
             (Screening Visit) and agree to remain abstinent, use barrier, or non-hormonal
             implanted contraceptives from study start until 14 days after the last dose of study
             drug;

          -  Be willing to limit alcohol use, if any, to 2 drinks or equivalent per day for the
             duration of the study and follow-up period;

          -  Be willing to avoid unaccustomed physical activity (e.g., starting a new weight
             lifting routine) for the duration of the study and follow-up period;

          -  Be willing to avoid chiropractic care, ultrasound and physical therapy from screening
             to Day 9;

          -  Be willing to avoid cold applications and other alternate treatments (e.g. massage,
             acupuncture etc.) on Day 1 and within 30 minutes prior to scheduled pain assessments
             on Day 3 and Day 8.

        Exclusion Criteria:

          -  Has low back pain that is related to, or known to be caused by malignancy,
             inflammatory disease (rheumatoid arthritis, ankylosing spondylitis, psoriatic
             arthritis, Reiter's syndrome), osteoporosis, ochronosis, vertebral fracture,
             infection, juvenile scoliosis, congenital malformation, or fibromyalgia. Note: the
             presence of radiographic degenerative disc disease is not an exclusion;

          -  Has signs or symptoms consistent with a neurologic, infectious, or fracture-related
             cause of acute low back pain;

          -  Has chronic low back pain and is experiencing an acute flare-up of the chronic back
             pain condition;

          -  Has radicular or myelopathic pain;

          -  Has a history of lumbar spine surgery;

          -  Is involved in an active civil lawsuit or workman's compensation claim pertaining to
             his/her low back pain;

          -  Has symptomatic depression that could interfere with the completion of the
             questionnaires;

          -  Is mentally or legally incapacitated, has significant emotional problems at the time
             of the study, or has a history of major psychiatric disorder, including any history of
             psychosis;

          -  Has a Body Mass Index (BMI) ≥ 40;

          -  Is allergic to, or has a history of a significant clinical or laboratory adverse
             experience associated with tizanidine, etoricoxib, methocarbamol, meloxicam, or any
             non-steroidal anti-inflammatory drug (NSAID);

          -  Is allergic to acetaminophen/paracetamol;

          -  Is currently a user (including &quot;recreational use&quot;) of any illicit drugs, or has a
             history (within 5 years) of drug or alcohol abuse;

          -  Has participated in another investigational drug study within the last 4 weeks;

          -  Has uncontrolled hypertension;

          -  Has systolic blood pressure (SBP) &lt; 105 or diastolic blood pressure (DBP) &lt; 65;

          -  Has a history of orthostatic hypotension;

          -  Has ischemic heart disease, peripheral arterial disease and/or cerebrovascular
             disease;

          -  Has a positive human immunodeficiency virus (HIV) test result, hepatitis B surface
             (HBS) antigen, or hepatitis C virus (HCV) test result;

          -  Has a history of hepatitis/hepatic disease that has been active within the previous
             year;

          -  Has a history of gastric, biliary, or small intestinal surgery or disease that results
             in clinical malabsorption;

          -  Has a history of neoplastic disease;

          -  Has any personal or family history of an inherited or acquired bleeding disorder;

          -  Is expected to undergo a planned surgical procedure or invasive diagnostic procedure
             during the course of the study;

          -  Is pregnant or breast-feeding, or expecting to conceive within the projected duration
             of the study;

          -  Has an active peptic ulcer or a history of inflammatory bowel disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2013</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
    <mesh_term>Tizanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

